32 results
Search Results
2. [Thought Experiments of Economic Surplus: Science and Economy in Ernst Mach's Epistemology].
- Author
-
Wulz M
- Subjects
- Germany, History, 19th Century, History, 20th Century, Economics history, Knowledge, Philosophy history, Research history, Science history, Thinking
- Abstract
Thought Experiments of Economic Surplus: Science and Economy in Ernst Mach's Epistemology. Thought experiments are an important element in Ernst Mach's epistemology: They facilitate amplifying our knowledge by experimenting with thoughts; they thus exceed the empirical experience and suspend the quest for immediate utility. In an economical perspective, Mach suggested that thought experiments depended on the production of an economic surplus based on the division of labor relieving the struggle for survival of the individual. Thus, as frequently emphasized, in Mach's epistemology, not only the 'economy of thought' is an important feature; instead, also the socioeconomic conditions of science play a decisive role. The paper discusses the mental and social economic aspects of experimental thinking in Mach's epistemology and examines those within the contemporary evolutionary, physiological, and economic contexts., (© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2015
- Full Text
- View/download PDF
3. What drives patent performance of German biotech firms? The impact of R&D subsidies, knowledge networks and their location.
- Author
-
Fornahl, Dirk, Broekel, Tom, and Boschma, Ron
- Subjects
BIOTECHNOLOGY ,ECONOMICS ,PATENTS ,RESEARCH ,BUSINESS enterprises - Abstract
This paper aims at explaining whether R&D subsidies, the engagement in collaboration networks and the location influence the patent activities of biotech firms in Germany! We demonstrate that R&D subsidies focusing on single firms do not increase patent intensity, while subsidies which are granted to joint R&D projects do so to a certain extent. The number of knowledge links firms have is not influencing performance, but the type of network partners has an effect. We found strong evidence that some but not too much cognitive distance between collaboration partners and being located in a cluster have a positive effect. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
4. The spatial pattern of localized R&D spillovers: an empirical investigation for Germany.
- Author
-
Bode, Eckhardt
- Subjects
ECONOMETRICS ,RESEARCH ,MATHEMATICAL models ,ECONOMICS ,STATISTICS - Abstract
The present paper employs spatial econometrics techniques to discriminate empirically between various economically plausible spatial patterns of interregional knowledge spillovers between west German planning regions in the 1990s. In general, interregional spillovers are found to contribute significantly to regional knowledge production. Due to fairly high spatial transaction costs, however, only a small fraction of the knowledge available in neighboring regions actually spills over. Consequently, the absolute contribution of `foreign' knowledge to a region's innovative performance is quite low. Moreover, only regions with low R&D density benefit from interregional spillovers. For regions with high R&D density they seem to be negligible. One reason for this maybe some sort of self-sufficiency in the R&D centers where researchers may have fewer incentives to consult researchers in other regions. Another reason for this may be the dominance of unidirectional knowledge flows from technological leaders to followers. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
5. Estimation of a physician practice cost function.
- Author
-
Kwietniewski, Lukas, Heimeshoff, Mareike, Schreyögg, Jonas, and Schreyögg, Jonas
- Subjects
MEDICAL care ,HOSPITAL costs ,PHYSICIANS' attitudes ,COST effectiveness ,DECISION making ,MEDICAL practice ,GROUP medical practice ,MEDICAL specialties & specialists ,OFFICE management ,MEDICAL offices ,COMPARATIVE studies ,ECONOMICS ,RESEARCH methodology ,MEDICAL cooperation ,MEDICINE ,PROBABILITY theory ,RESEARCH ,EVALUATION research - Abstract
Objective: The goal of the present paper is to provide evidence on the behavior of physician practice cost functions.Data Sources: Our study is based on the data of 3686 physician practices in Germany for the years 2006 to 2008.Study Design: We apply a translog functional form and include a comprehensive set of variables that have not been previously used in this context. A system of four equations using three-stage least squares is estimated.Principal Findings: We find that a higher degree of specialization leads to a decrease in costs, whereas quality certification increases costs. Costs of group practices are higher than of solo practices. The latter finding can be explained by the existence of indivisibilities of expensive technical equipment. Smaller practices do not reach the critical mass to invest in certain technologies, which leads to differences in the type of health care services provided by different practice types.Conclusions: This is the first study to use physician practices as the unit of observation and to consider the endogenous character of physician input. Our results suggest that identifying factors that influence physician practice costs is important for providing evidence-based physician payment systems and to enable decision-makers to set incentives effectively. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
6. Does diabetes prevention pay for itself? Evaluation of the M.O.B.I.L.I.S. program for obese persons.
- Author
-
Häußler, Jan and Breyer, Friedrich
- Subjects
DIABETES prevention ,COST analysis ,OBESITY ,MARKOV processes ,UNHEALTHY lifestyles ,PREVENTIVE health services ,COMPARATIVE studies ,COST effectiveness ,TYPE 1 diabetes ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,TYPE 2 diabetes ,RESEARCH ,EVALUATION research ,EVALUATION of human services programs ,ECONOMICS - Abstract
In response to the growing burden of obesity, public primary prevention programs against obesity have been widely recommended. Several studies have estimated the cost-effectiveness of diabetes-prevention trials for different countries. Nevertheless, it is still controversial if prevention conducted in more real-world settings and among people with increased risk but not yet exhibiting increased glucose tolerance can be a cost-saving strategy to cope with the obesity epidemic. We examine this question in a simulation model based on the results of the M.O.B.I.L.I.S program, a German lifestyle intervention to reduce obesity, which is directed on the high-risk group of people who are already obese. The contribution of this paper is the use of 4-year follow-up data on the intervention group and a comparison with a control group formed by SOEP respondents as inputs in a Markov model of the long-term cost savings through this intervention due to the prevention of type 2 diabetes. We show that from the point of view of a health insurer, these programs can pay for themselves. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Annotated Listing of New Books: Other Special Topics.
- Subjects
ECONOMICS ,RESEARCH ,FERTILITY ,BIRTH control ,SOCIAL security ,DEVELOPING countries ,FINANCE ,ECONOMIC policy - Abstract
The article evaluates the journal "Economics," which reports results of German research studies in the field of economics, published biannually by the Institute for Scientific Cooperation.
- Published
- 1997
8. Strategies for a risky business: How drug dealers manage customers, suppliers and competitors in Italy, Slovenia and Germany.
- Author
-
Tzvetkova, Marina, Pardal, Mafalda, Disley, Emma, Rena, Alice, Talic, Sanela, and Forberger, Sarah
- Subjects
- *
DRUG dealers , *RISK management in business , *BUSINESS planning , *DRUG supply & demand , *DRUG traffic , *ECONOMIC impact of crime , *BUSINESS , *COCAINE , *COMPARATIVE studies , *COMPETITION (Psychology) , *CONFLICT (Psychology) , *CRIMINALS , *ECONOMICS , *HEROIN , *INTERPERSONAL relations , *INTERVIEWING , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *TRUST , *EVALUATION research , *ORGANIZATIONAL goals ,BUSINESS & economics - Abstract
Background: A growing body of literature aims to improve understanding of the operations of drug trafficking markets through conducting interviews with dealers and traffickers. Insight into how these individuals conduct business can provide evidence to inform the efforts by policy makers, law enforcement and practitioners to disrupt illicit markets. This paper aims to make a contribution to this evidence base by extending the number of European countries in which interviews have been conducted with incarcerated drug dealers and traffickers.Methods: It draws on interviews with 135 men convicted of offences related to the distribution or sale of heroin or cocaine and imprisoned in Italy, Slovenia and Germany. The research was conducted as part of the Reframing Addictions Project (ALICE-RAP) funded by the European Commission. The sample was diverse. It included a range of nationalities and some individuals who were members of organised crime groups. The majority of the interviewees were dealers who sold at the retail and street level, but there were some who were importers and wholesalers.Findings: Most dealers in each of the three countries reported having more than one regular supplier, and were able to respond to periods of over and under supply without losing customers. Supply arrangements varied in terms of frequency and quantities bought. Dealers engaged in repeated transactions and their relationships with customers were based on trust and reputation. Dealers aimed to sell to regular customers and to provide drugs of good quality. While dealers sought to maximise their profits by cutting drugs with cutting agents, the quality of drugs that they sold could affect their reputation and thus their profits and position in the market. Lastly, while there are some significant differences in the approach between those involved in organised crime groups and those who are not, and between street dealers and those operating at higher levels of the market, there were striking similarities in terms of the day-to-day operational concerns and modes of relationship management.Conclusions: Interviewees' arrangements for securing supplies of drugs provide support to the notion that drug markets are resilient and flexible. Our findings correspond with other empirical research in relation to the centrality of trust in the practical operation of supply and sale of drugs. The research highlights some differences, but important similarities between dealers who were part of organised crime groups and those who were not; dealers all faced some common challenges and adopted some common responses to these. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Workplace health promotion and labour market performance of employees.
- Author
-
Huber, Martin, Lechner, Michael, and Wunsch, Conny
- Subjects
- *
INDUSTRIAL hygiene , *HEALTH promotion , *LABOR market , *ORGANIZATIONAL performance , *INDUSTRIAL relations , *PANEL analysis , *COMPARATIVE studies , *COST control , *DECISION making , *DEMOGRAPHY , *JOB satisfaction , *LABOR turnover , *MANAGEMENT , *RESEARCH methodology , *MEDICAL cooperation , *HEALTH policy , *OCCUPATIONAL health services , *PROBABILITY theory , *RESEARCH , *EVALUATION research , *SICK leave , *ECONOMICS - Abstract
This paper investigates the average effects of firm-provided workplace health promotion measures on labour market outcomes of the firms' employees. Exploiting linked employer-employee panel data that consist of rich survey-based and administrative information on firms, workers and regions, we apply a flexible propensity score matching approach that controls for selection on observables and time-constant unobserved factors. While the effects of analysing sickness absenteeism appear to be rather limited, our results suggest that health circles/courses increase tenure and job stability across various age groups. A key finding is that health circles/courses strengthen the labour force attachment of elderly employees (51-60), implying potential cost savings for public transfer schemes such as unemployment insurance or early retirement schemes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Exploratory comparison of Healthcare costs and benefits of the UK's Covid-19 response with four European countries.
- Author
-
Thom, Howard, Walker, Josephine, Vickerman, Peter, and Hollingworth, Will
- Subjects
RESEARCH ,COVID-19 ,MEDICAL care costs ,COST control ,HOSPITAL care ,DESCRIPTIVE statistics ,DEATH ,GOVERNMENT aid ,COVID-19 testing ,QUALITY-adjusted life years ,ECONOMICS - Abstract
Background In responding to Covid-19, governments have tried to balance protecting health while minimizing gross domestic product (GDP) losses. We compare health-related net benefit (HRNB) and GDP losses associated with government responses of the UK, Ireland, Germany, Spain and Sweden from UK healthcare payer perspective. Methods We compared observed cases, hospitalizations and deaths under 'mitigation' to modelled events under 'no mitigation' to 20 July 2020. We thus calculated healthcare costs, quality adjusted life years (QALYs), and HRNB at £20,000/QALY saved by each country. On per population (i.e. per capita) basis, we compared HRNB with forecast reductions in 2020 GDP growth (overall or compared with Sweden as minimal mitigation country) and qualitatively and quantitatively described government responses. Results The UK saved 3.17 (0.32–3.65) million QALYs, £33 (8–38) billion healthcare costs and £1416 (220–1637) HRNB per capita at £20,000/QALY. Per capita, this is comparable to £1455 GDP loss using Sweden as comparator and offsets 46.1 (7.1–53.2)% of total £3075 GDP loss. Germany, Spain, and Sweden had greater HRNB per capita. These also offset a greater percentage of total GDP losses per capita. Ireland fared worst on both measures. Countries with more mask wearing, testing, and population susceptibility had better outcomes. Highest stringency responses did not appear to have best outcomes. Conclusions Our exploratory analysis indicates the benefit of government Covid-19 responses may outweigh their economic costs. The extent that HRNB offset economic losses appears to relate to population characteristics, testing levels, and mask wearing, rather than response stringency. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. 'It was a big monetary cut'—A qualitative study on financial toxicity analysing patients' experiences with cancer costs in Germany.
- Author
-
Lueckmann, Sara Lena, Schumann, Nadine, Hoffmann, Laura, Roick, Julia, Kowalski, Christoph, Dragano, Nico, and Richter, Matthias
- Subjects
CANCER patient psychology ,CONTENT analysis ,ECONOMIC aspects of diseases ,INCOME ,HEALTH insurance ,INTERVIEWING ,RESEARCH methodology ,MEDICAL care costs ,RESEARCH ,RESEARCH funding ,TUMORS ,QUALITATIVE research ,FINANCIAL management - Abstract
Receiving information about expected costs promptly after a cancer diagnosis through psycho‐oncology care or social counselling is crucial for patients to be prepared for the financial impact. Nevertheless, less is known about financial impacts for cancer patients in countries with statutory health insurance. This study aims to explore the full scope of costs that constitute the financial impact of a cancer diagnosis in Germany and to identify the reasons for high financial decline. Semistructured interviews with 39 cancer patients were conducted between May 2017 and April 2018. Narratives were analysed via qualitative content analysis. Several factors influenced cancer patients' indirect costs and direct medical and non‐medical costs. For many patients, these changes resulted in higher indirect costs caused by income losses, especially when surcharges for shift work, travel expenses or company benefits ceased and were not reimbursed. Higher direct medical costs were caused by co‐payments and additional non‐refundable costs. Non‐medical costs were reported to increase for some patients and to decrease for others, as for example, leisure activity costs either increasing because of pampering oneself to cope with the diagnosis and undergoing therapy or decreasing because of not being able to participate in leisure activities during therapy. When analysing the financial impacts of individuals' total costs, we found that some patients experienced no financial decline or an overall financial increase. Most patients experienced overall higher costs, and income loss was the main driver of a high financial decline. Nevertheless, decreased non‐medical costs due to lower work‐related and leisure activity costs could compensate for these higher costs. Cancer patients are confronted with a variety of changes in their financial situations, even in countries with statutory health insurance. Screening for cancer patients with a high risk of financial decline should consider any effects on indirect costs and direct medical and nonmedical costs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Choice and performance of governance mechanisms: matching alliance governance to asset type.
- Author
-
Hoetker, Glenn and Mellewigt, Thomas
- Subjects
RESEARCH ,CORPORATE governance ,STRATEGIC alliances (Business) ,BUSINESS partnerships ,TELECOMMUNICATION ,ASSETS (Accounting) ,ECONOMICS ,FINANCE - Abstract
Formal and relational governance mechanisms are used in strategic alliances to coordinate resources and mitigate the risk of opportunistic behavior. While recent work has shown that these approaches are not mutually exclusive, we understand little about when one approach is superior to the other. Using data on the governance choices and subsequent performance of alliances in the German telecommunications industry, we find that the optimal configuration of formal and relational governance mechanisms depends on the assets involved in an alliance, with formal mechanisms best suited to property-based assets and relational governance best suited to knowledge-based assets. Furthermore, a mismatch between governance mechanisms and asset type can harm the performance of the alliance. Our findings contribute to transaction cost economics, the literature on relational governance, and recent work studying their interaction. Copyright © 2009 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
13. Norovirus Gastroenteritis among Hospitalized Patients, Germany, 2007-2012.
- Author
-
Kowalzik, Frank, Binder, Harald, Zöller, Daniela, Riera-Montes, Margarita, Clemens, Ralf, Verstraeten, Thomas, and Zepp, Fred
- Subjects
NOROVIRUS diseases ,GASTROENTERITIS ,HOSPITAL care ,MEDICAL care costs ,INTERNATIONAL Statistical Classification of Diseases & Related Health Problems ,ACADEMIC medical centers ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH evaluation ,RNA viruses ,EVALUATION research ,MEDICAL coding ,ECONOMICS - Abstract
We estimated numbers of hospitalizations for norovirus gastroenteritis (NGE) and associated medical costs in Germany, where norovirus testing is high because reimbursement is affected. We extracted aggregate data for patients hospitalized with a primary or secondary code from the International Classification of Diseases, 10th Revision (ICD-10), NGE diagnosis during 2007-2012 from the German Federal Statistics Office. We assessed reliability of the coding system in patient records from a large academic hospital. Approximately 53,000-90,000 NGE hospitalizations occurred annually in Germany (21,000-33,000 with primary and 32,000-57,000 with secondary ICD-10-coded NGE diagnoses). Rates of hospitalization with NGE as primary diagnosis were highest in children <2 years of age; rates of hospitalization with NGE as secondary diagnosis were highest in adults >85 years of age. The average annual reimbursed direct medical cost of NGE hospitalizations was €31-43 million. Among patients with a NGE ICD-10 code, 87.6% had positive norovirus laboratory results. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. The KTx360°-study: a multicenter, multisectoral, multimodal, telemedicine-based follow-up care model to improve care and reduce health-care costs after kidney transplantation in children and adults.
- Author
-
Pape, L., de Zwaan, M., Tegtbur, U., Feldhaus, F., Wolff, J. K., Schiffer, L., Lerch, C., Hellrung, N., Kliem, V., Lonnemann, G., Nolting, H. D., and Schiffer, M.
- Subjects
KIDNEY transplantation ,TELEMEDICINE ,MEDICAL case management ,EXERCISE physiology ,PSYCHOSOMATIC medicine ,PATIENT compliance ,CARDIOVASCULAR diseases risk factors ,SURVIVAL analysis (Biometry) ,COMPARATIVE studies ,COST control ,EXPERIMENTAL design ,INTERNET ,PATIENT aftercare ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,QUALITY of life ,RESEARCH ,VIDEOCONFERENCING ,COMORBIDITY ,EVALUATION research ,ECONOMICS - Abstract
Background: Follow-up care after kidney transplantation is performed in transplant centers as well as in local nephrologist's practices in Germany. However, organized integrated care of these different sectors of the German health care system is missing. This organizational deficit as well as non-adherence of kidney recipients and longterm cardiovascular complications are major reasons for an impaired patient and graft survival.Methods: The KTx360° study is supported by a grant from the Federal Joint Committee of the Federal Republic of Germany. The study will include 448 (39 children) incident patients of all ages with KTx after study start in May 2017 and 963 (83 children) prevalent patients with KTx between 2010 and 2016. The collaboration between transplant centers and nephrologists in private local practices will be supported by internet-based case-files and scheduled virtual visits (patient consultation via video conferencing). At specified points of the care process patients will receive cardiovascular and adherence assessments and respective interventions. Care will be coordinated by an additional case management. The goals of the study will be evaluated by an independent institute using claims data from the statutory health insurances and data collected from patients and their caregivers during study participation. To model longitudinal changes after transplantation and differences in changes and levels of immunosuppresive therapy after transplantation between study participants and historical data as well as data from control patients who do not participate in KTx360°, adjusted regression analyses, such as mixed models with repeated measures, will be used. Relevant confounders will be controlled in all analyses.Discussion: The study aims to prolong patient and graft survival, to reduce avoidable hospitalizations, co-morbidities and health care costs, and to enhance quality of life of patients after kidney transplantation.Trial Registration: ISRCTN29416382 (retrospectively registered on 05.05.2017). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey.
- Author
-
Ding, Bo and Small, Mark
- Subjects
ADRENOCORTICAL hormones ,HORMONE therapy ,DRUG therapy for asthma ,BRONCHODILATOR agents ,ASTHMA ,COMPARATIVE studies ,ECONOMIC aspects of diseases ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,QUESTIONNAIRES ,RESEARCH ,EVALUATION research ,CROSS-sectional method ,ECONOMICS ,THERAPEUTICS - Abstract
Introduction: Most asthma patients have mild disease, although the burden of mild asthma is not well understood nor studied. Some evidence suggests that many patients with mild asthma experience suboptimal symptom control and exacerbations. This study characterizes the burden of illness and treatment patterns among patients with a confirmed diagnosis of mild asthma, defined as GINA Step 1 or Step 2, and residing in China, France, Germany, Italy, Japan, Spain, the United Kingdom, or the United States.Methods: The Respiratory Disease-Specific Programme prospective cross-sectional survey was conducted with primary care and specialty physicians in each of the eight countries. Physician and patient surveys assessed demographic and clinical characteristics, frequency and timing of asthma symptoms, exacerbations, and rescue inhaler usage, the most recent FEV1% predicted, and healthcare utilization. GINA Step was determined by prescribed treatment regimen. GINA Step 1 patients were prescribed as-needed reliever medication and Step 2 required treatment with a low-dose inhaled corticosteroid, leukotriene receptor antagonist, or theophylline. Treatment adherence was assessed with the Morisky Medication Adherence scale, disease control with the Asthma Control Test, and work and activity impairments with the Work Productivity and Activity Impairment scale.Results: The sample included 1115 GINA Step 1 and 2 patients, with 53% classified as Step 2. Overall asthma control was suboptimal, with reports of nocturnal symptoms (40.6%), symptom worsening (10.5%), and rescue inhaler usage in the last 4 weeks (33.6%). 25% of patients were uncontrolled. The overall mean number of exacerbations in the last 12 months was 0.4, with a higher frequency of exacerbations in Step 2 patients who also experienced more exacerbations requiring treatment intensification, an emergency department visit, or hospitalization.Conclusion: Mild asthma imposes a substantial burden on patients, establishing the need for comprehensive management plans and ongoing support for treatment adherence.Funding: AstraZeneca. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.
- Author
-
Karl, Florian M., Holle, Rolf, Bals, Robert, Greulich, Timm, Jörres, Rudolf A., Karch, Annika, Koch, Armin, Karrasch, Stefan, Leidl, Reiner, Schulz, Holger, Vogelmeier, Claus, Wacker, Margarethe E., and COSYCONET Study Group
- Subjects
GENETIC disorders ,ALPHA 1-antitrypsin ,OBSTRUCTIVE lung diseases patients ,MEDICAL care costs ,MEDICAL quality control ,REGRESSION analysis ,QUALITY of life ,MENTAL health ,MEDICAL care cost statistics ,ALPHA 1-antitrypsin deficiency ,COMPARATIVE studies ,DEMOGRAPHY ,ECONOMIC aspects of diseases ,RESEARCH methodology ,OBSTRUCTIVE lung diseases ,MEDICAL cooperation ,QUESTIONNAIRES ,RESEARCH ,COMORBIDITY ,EVALUATION research ,DISEASE prevalence ,PSYCHOLOGY ,ECONOMICS - Abstract
Background: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease.Methods: Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared between 131 AATD patients (106 with, 25 without augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the COSYCONET COPD cohort. The medication costs of AT were excluded from all analyses to reveal differences associated with morbidity profiles. The association of AATD (with/without AT) with costs or HRQL was examined using generalized linear regression modelling (GLM) adjusting for age, sex, GOLD grade, BMI, smoking status, education and comorbidities.Results: Adjusted mean direct annual costs were €6,099 in AATD patients without AT, €7,117 in AATD patients with AT (excluding costs for AT), and €7,460 in COPD patients without AATD. AATD with AT was significantly associated with higher outpatient (+273%) but lower inpatient (-35%) and medication costs (-10%, disregarding AT) compared with COPD patients without AATD. There were no significant differences between groups regarding indirect costs and HRQL.Conclusion: Apart from AT costs, AATD patients tended to have lower, though not significant, overall costs and similar HRQL compared to COPD patients without AATD. AT was not associated with lower costs or higher HRQL.Trial Registration: NCT01245933. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Applying for, reviewing and funding public health research in Germany and beyond.
- Author
-
Gerhardus, Ansgar, Becher, Heiko, Groenewegen, Peter, Mansmann, Ulrich, Meyer, Thorsten, Pfaff, Holger, Puhan, Milo, Razum, Oliver, Rehfuess, Eva, Sauerborn, Rainer, Strech, Daniel, Wissing, Frank, Zeeb, Hajo, and Hummers-Pradier, Eva
- Subjects
PUBLIC health research ,HEALTH care industry ,RESEARCH grants ,HEALTH education ,CONSENSUS (Social sciences) ,ECONOMICS ,ENDOWMENTS ,ETHICS ,EXPERIMENTAL design ,MEDICAL care research ,MEDICAL protocols ,PROFESSIONAL peer review ,PUBLIC health ,INSTITUTIONAL review boards ,RESEARCH personnel - Abstract
Public health research is complex, involves various disciplines, epistemological perspectives and methods, and is rarely conducted in a controlled setting. Often, the added value of a research project lies in its inter- or trans-disciplinary interaction, reflecting the complexity of the research questions at hand. This creates specific challenges when writing and reviewing public health research grant applications. Therefore, the German Research Foundation (DFG), the largest independent research funding organization in Germany, organized a round table to discuss the process of writing, reviewing and funding public health research. The aim was to analyse the challenges of writing, reviewing and granting scientific public health projects and to improve the situation by offering guidance to applicants, reviewers and funding organizations. The DFG round table discussion brought together national and international public health researchers and representatives of funding organizations. Based on their presentations and discussions, a core group of the participants (the authors) wrote a first draft on the challenges of writing and reviewing public health research proposals and on possible solutions. Comments were discussed in the group of authors until consensus was reached. Public health research demands an epistemological openness and the integration of a broad range of specific skills and expertise. Applicants need to explicitly refer to theories as well as to methodological and ethical standards and elaborate on why certain combinations of theories and methods are required. Simultaneously, they must acknowledge and meet the practical and ethical challenges of conducting research in complex real life settings. Reviewers need to make the rationale for their judgments transparent, refer to the corresponding standards and be explicit about any limitations in their expertise towards the review boards. Grant review boards, funding organizations and research ethics committees need to be aware of the specific conditions of public health research, provide adequate guidance to applicants and reviewers, and ensure that processes and the expertise involved adequately reflect the topic under review. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
- Author
-
Vokó, Zoltan, Kei Long Cheung, Józwiak-Hagymásy, Judit, Wolfenstetter, Silke, Jones, Teresa, Muñoz, Celia, Evers, Silvia M.A.A., Hiligsmann, Mickaël, de Vries, Hein, Pokhrel, Subhash, Cheung, Kei Long, and EQUIPT Study Group
- Subjects
MEDICAL technology evaluation ,STAKEHOLDER analysis ,PREVENTION of tobacco use ,RATE of return ,INVESTMENT policy ,DECISION making ,SMOKING ,SMOKING prevention ,ATTITUDE (Psychology) ,COGNITION ,COMPARATIVE studies ,COST effectiveness ,EXECUTIVES ,HEALTH attitudes ,INVESTMENTS ,RESEARCH methodology ,MEDICAL cooperation ,HEALTH policy ,MOTIVATION (Psychology) ,HEALTH outcome assessment ,PUBLIC opinion ,QUALITY assurance ,RESEARCH ,SMOKING cessation ,EVIDENCE-based medicine ,PROFESSIONAL practice ,EVALUATION research ,ECONOMICS - Abstract
Background: The European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) project aimed to study transferability of economic evidence by co-creating the Tobacco Return On Investment (ROI) tool, previously developed in the United Kingdom, for four sample countries (Germany, Hungary, Spain and the Netherlands). The EQUIPT tool provides policymakers and stakeholders with customized information about the economic and wider returns on the investment in evidence-based tobacco control, including smoking cessation interventions. A Stakeholder Interview Survey was developed to engage with the stakeholders in early phases of the development and country adaptation of the ROI tool. The survey assessed stakeholders' information needs, awareness about underlying principles used in economic analyses, opinion about the importance, effectiveness and cost-effectiveness of tobacco control interventions, and willingness to use a Health Technology Assessment (HTA) tool such as the ROI tool.Methods: A cross sectional study using a mixed method approach was conducted among participating stakeholders in the sample countries and the United Kingdom. The individual questionnaire contained open-ended questions as well as single choice and 7- or 3-point Likert-scale questions. The results corresponding to the priority and needs assessment and to the awareness of stakeholders about underlying principles used in economic analysis are analysed by country and stakeholder categories.Results: Stakeholders considered it important that the decisions on the investments in tobacco control interventions should be supported by scientific evidence, including prevalence of smoking, cost of smoking, quality of life, mortality due to smoking, and effectiveness, cost-effectiveness and budget impact of smoking cessation interventions. The proposed ROI tool was required to provide this granularity of information. The majority of the stakeholders were aware of the general principles of economic analyses used in decision making contexts but they did not appear to have in-depth knowledge about specific technical details. Generally, stakeholders' answers showed larger variability by country than by stakeholder category.Conclusions: Stakeholders across different European countries viewed the use of HTA evidence to be an important factor in their decision-making process. Further, they considered themselves to be capable of interpreting the results from a ROI tool and were highly motivated to use it. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. Drug overprescription in nursing homes: an empirical evaluation of administrative data.
- Author
-
Stroka, Magdalena and Stroka, Magdalena A
- Subjects
MEDICATION errors ,DRUG prescribing ,MEDICAL care costs ,LONG-term health care ,NURSING care facilities ,DRUG utilization statistics ,ALGORITHMS ,ANALGESICS ,ANTIDEPRESSANTS ,ANTIPSYCHOTIC agents ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,PROBABILITY theory ,RESEARCH ,USER charges ,EVALUATION research ,SENIOR housing ,STATISTICAL models ,ECONOMICS - Abstract
A widely discussed shortcoming of long-term care in nursing homes for the elderly is the inappropriate or suboptimal drug utilization, particularly of psychotropic drugs. Using administrative data from the largest sickness fund in Germany, this study was designed to estimate the effect of institutionalization on the drug intake of the frail elderly. Difference-in-differences propensity score matching techniques were used to compare drug prescriptions for the frail elderly who entered a nursing home with those who remained in the outpatient care system; findings suggest that nursing home residents receive more doses of antipsychotics, antidepressants, and analgesics. The potential overprescription correlates with estimated drug costs of about €87 million per year. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.
- Author
-
Stollenwerk, Björn, Welchowski, Thomas, Vogl, Matthias, Stock, Stephanie, and Stollenwerk, Björn
- Subjects
MEDICAL research ,COST estimates ,COST effectiveness ,MEDICAL care costs ,LOGISTIC regression analysis ,OBSTRUCTIVE lung diseases ,COMPARATIVE studies ,ECONOMIC aspects of diseases ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,ACQUISITION of data ,STATISTICAL models ,ECONOMICS - Abstract
Despite the increasing availability of routine data, no analysis method has yet been presented for cost-of-illness (COI) studies based on massive data. We aim, first, to present such a method and, second, to assess the relevance of the associated gain in numerical efficiency. We propose a prevalence-based, top-down regression approach consisting of five steps: aggregating the data; fitting a generalized additive model (GAM); predicting costs via the fitted GAM; comparing predicted costs between prevalent and non-prevalent subjects; and quantifying the stochastic uncertainty via error propagation. To demonstrate the method, it was applied to aggregated data in the context of chronic lung disease to German sickness funds data (from 1999), covering over 7.3 million insured. To assess the gain in numerical efficiency, the computational time of the innovative approach has been compared with corresponding GAMs applied to simulated individual-level data. Furthermore, the probability of model failure was modeled via logistic regression. Applying the innovative method was reasonably fast (19 min). In contrast, regarding patient-level data, computational time increased disproportionately by sample size. Furthermore, using patient-level data was accompanied by a substantial risk of model failure (about 80 % for 6 million subjects). The gain in computational efficiency of the innovative COI method seems to be of practical relevance. Furthermore, it may yield more precise cost estimates. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation.
- Author
-
Adarkwah, Charles Christian, Sadoghi, Amirhossein, and Gandjour, Afschin
- Subjects
LEISURE ,COMPARATIVE studies ,COST effectiveness ,HEALTH attitudes ,HEALTH status indicators ,MATHEMATICAL models ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,TIME ,THEORY ,EVALUATION research ,RANDOMIZED controlled trials ,QUALITY-adjusted life years ,ECONOMICS - Abstract
There has been a debate on whether cost-effectiveness analysis should consider the cost of consumption and leisure time activities when using the quality-adjusted life year as a measure of health outcome under a societal perspective. The purpose of this study was to investigate whether the effects of ill health on consumptive activities are spontaneously considered in a health state valuation exercise and how much this matters. The survey enrolled patients with inflammatory bowel disease in Germany (n = 104). Patients were randomized to explicit and no explicit instruction for the consideration of consumption and leisure effects in a time trade-off (TTO) exercise. Explicit instruction to consider non-health-related utility in TTO exercises did not influence TTO scores. However, spontaneous consideration of non-health-related utility in patients without explicit instruction (60% of respondents) led to significantly lower TTO scores. Results suggest an inclusion of consumption costs in the numerator of the cost-effectiveness ratio, at least for those respondents who spontaneously consider non-health-related utility from treatment. Results also suggest that exercises eliciting health valuations from the general public may include a description of the impact of disease on consumptive activities. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries.
- Author
-
Bekelman, Justin E., Halpern, Scott D., Blankart, Carl Rudolf, Bynum, Julie P., Cohen, Joachim, Fowler, Robert, Kaasa, Stein, Kwietniewski, Lukas, Melberg, Hans Olav, Onwuteaka-Philipsen, Bregje, Oosterveld-Vlug, Mariska, Pring, Andrew, Schreyögg, Jonas, Ulrich, Connie M., Verne, Julia, Wunsch, Hannah, Emanuel, Ezekiel J., and International Consortium for End-of-Life Research (ICELR)
- Subjects
COMPARATIVE studies ,DEMOGRAPHY ,HOSPITAL care ,HOSPITAL charges ,HOSPITAL emergency services ,INTENSIVE care units ,LUNG tumors ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,PATIENT satisfaction ,RESEARCH ,RESEARCH funding ,TERMINAL care ,TIME ,TUMORS ,DEVELOPED countries ,ATTITUDES toward death ,EVALUATION research ,RETROSPECTIVE studies ,HOSPITAL mortality ,ECONOMICS - Abstract
Importance: Differences in utilization and costs of end-of-life care among developed countries are of considerable policy interest.Objective: To compare site of death, health care utilization, and hospital expenditures in 7 countries: Belgium, Canada, England, Germany, the Netherlands, Norway, and the United States.Design, Setting, and Participants: Retrospective cohort study using administrative and registry data from 2010. Participants were decedents older than 65 years who died with cancer. Secondary analyses included decedents of any age, decedents older than 65 years with lung cancer, and decedents older than 65 years in the United States and Germany from 2012.Main Outcomes and Measures: Deaths in acute care hospitals, 3 inpatient measures (hospitalizations in acute care hospitals, admissions to intensive care units, and emergency department visits), 1 outpatient measure (chemotherapy episodes), and hospital expenditures paid by insurers (commercial or governmental) during the 180-day and 30-day periods before death. Expenditures were derived from country-specific methods for costing inpatient services.Results: The United States (cohort of decedents aged >65 years, N = 211,816) and the Netherlands (N = 7216) had the lowest proportion of decedents die in acute care hospitals (22.2.% and 29.4%, respectively). A higher proportion of decedents died in acute care hospitals in Belgium (N = 21,054; 51.2%), Canada (N = 20,818; 52.1%), England (N = 97,099; 41.7%), Germany (N = 24,434; 38.3%), and Norway (N = 6636; 44.7%). In the last 180 days of life, 40.3% of US decedents had an intensive care unit admission compared with less than 18% in other reporting nations. In the last 180 days of life, mean per capita hospital expenditures were higher in Canada (US $21,840), Norway (US $19,783), and the United States (US $18,500), intermediate in Germany (US $16,221) and Belgium (US $15,699), and lower in the Netherlands (US $10,936) and England (US $9342). Secondary analyses showed similar results.Conclusions and Relevance: Among patients older than 65 years who died with cancer in 7 developed countries in 2010, end-of-life care was more hospital-centric in Belgium, Canada, England, Germany, and Norway than in the Netherlands or the United States. Hospital expenditures near the end of life were higher in the United States, Norway, and Canada, intermediate in Germany and Belgium, and lower in the Netherlands and England. However, intensive care unit admissions were more than twice as common in the United States as in other countries. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
23. Time-dependent ambulance allocation considering data-driven empirically required coverage.
- Author
-
Degel, Dirk, Wiesche, Lara, Rachuba, Sebastian, and Werners, Brigitte
- Subjects
AMBULANCE service ,EMPIRICAL research ,EMERGENCY medical services ,MATHEMATICAL optimization ,INTEGER programming ,LINEAR programming ,AMBULANCES ,COMMUNITY health services ,COMPARATIVE studies ,GEOGRAPHIC information systems ,MATHEMATICAL models ,RESEARCH methodology ,MEDICAL quality control ,MEDICAL cooperation ,REGRESSION analysis ,RESEARCH ,RESOURCE allocation ,TIME ,URBAN health ,CITY dwellers ,THEORY ,EVALUATION research ,ECONOMICS - Abstract
Empirical studies considering the location and relocation of emergency medical service (EMS) vehicles in an urban region provide important insight into dynamic changes during the day. Within a 24-hour cycle, the demand, travel time, speed of ambulances and areas of coverage change. Nevertheless, most existing approaches in literature ignore these variations and require a (temporally and spatially) fixed (double) coverage of the planning area. Neglecting these variations and fixation of the coverage could lead to an inaccurate estimation of the time-dependent fleet size and individual positioning of ambulances. Through extensive data collection, now it is possible to precisely determine the required coverage of demand areas. Based on data-driven optimization, a new approach is presented, maximizing the flexible, empirically determined required coverage, which has been adjusted for variations due to day-time and site. This coverage prevents the EMS system from unavailability of ambulances due to parallel operations to ensure an improved coverage of the planning area closer to realistic demand. An integer linear programming model is formulated in order to locate and relocate ambulances. The use of such a programming model is supported by a comprehensive case study, which strongly suggests that through such a model, these objectives can be achieved and lead to greater cost-effectiveness and quality of emergency care. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Determination of the efficacy of EVICEL™ on blood loss in orthopaedic surgery after total knee replacement: study protocol for a randomised controlled trial.
- Author
-
Budde, S., Noll, Y., Zieglschmid, V., Schroeder, C., Koch, A., and Windhagen, H.
- Subjects
FIBRIN tissue adhesive ,HEMORRHAGE prevention ,ORTHOPEDIC surgery ,TOTAL knee replacement ,RANDOMIZED controlled trials ,BLOOD transfusion ,HEMOSTASIS ,KNEE surgery ,PREVENTION of surgical complications ,SURGICAL blood loss ,ELECTROCOAGULATION (Medicine) ,COMPARATIVE studies ,CONVALESCENCE ,COST effectiveness ,EXPERIMENTAL design ,HEMORRHAGE ,HEMOSTATICS ,HOSPITAL costs ,RANGE of motion of joints ,KINEMATICS ,KNEE ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,RESEARCH protocols ,RESEARCH ,SURGICAL complications ,TIME ,WOUND healing ,EVALUATION research ,TREATMENT effectiveness ,BLIND experiment ,ECONOMICS ,PREVENTION ,THERAPEUTICS - Abstract
Background: After total knee replacement, overall blood loss is often underestimated, although it exceeds the visible blood loss caused by bleeding into the tissues or into the joint. The use of fibrin sealants during surgery has been suggested to reduce perioperative blood loss and transfusion rates and may be beneficial for patient recovery and the postoperative function of the joint.Methods/design: This will be a single-centre, single-blinded, randomised controlled trial with a parallel design, for which 68 patients undergoing total knee replacement will be recruited and followed up at 3, 6 and 12 months; 34 will be control patients who will receive the standard orthopaedic surgery treatment (electrocoagulation), and the other 34 will receive the same treatment plus 5 ml EVICEL™ applied during surgery and used according to the manufacturer's instructions. The primary objective is to test the null hypothesis that the effect of EVICEL™ for controlling haemostasis and reducing postoperative blood loss in patients undergoing total knee replacement is not superior to the use of electrocoagulation alone. The secondary objective is to show that EVICEL™ reduces the need for transfusion, increases range of motion, improves clinical outcome and wound healing, and reduces the need for analgesics. The tertiary objective is to show that EVICEL™ reduces the costs of total knee replacement treatment.Discussion: So far, studies on the effect of fibrin sealants in total knee replacement have delivered inconsistent and ambivalent results, indicating that there is still a need for high-evidence studies as proposed in the presented study protocol.Trial Registration: German registration number DRKS00007564; date of registration: 26 November 2014. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
25. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
- Author
-
Mickisch, G., Gore, M., Escudier, B., Procopio, G., Walzer, S., and Nuijten, M.
- Subjects
RENAL cell carcinoma ,BEVACIZUMAB ,INTERFERONS ,DISEASE progression ,NEUTROPENIA ,FATIGUE (Physiology) ,HEMORRHAGE ,DRUG side effects ,HOSPITAL care ,CLINICAL trials ,MEDICAL care cost statistics ,ANTINEOPLASTIC agents ,BLOOD diseases ,COMPARATIVE studies ,GASTROINTESTINAL diseases ,HOSPITAL costs ,HETEROCYCLIC compounds ,HYPERTENSION ,KIDNEY tumors ,RESEARCH methodology ,MEDICAL cooperation ,MONOCLONAL antibodies ,PROTEINS ,NEOVASCULARIZATION inhibitors ,RECOMBINANT proteins ,RESEARCH ,VENOUS thrombosis ,EVALUATION research ,INDOLE compounds ,ECONOMICS ,PROTEIN kinase inhibitors ,THERAPEUTICS - Abstract
Background: Bevacizumab plus interferon-alpha2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles; therefore, costs for managing adverse events may be an important factor in selecting therapy.Methods: Costs of managing adverse events affecting patients with metastatic RCC eligible for treatment with bevacizumab plus IFN or sunitinib were evaluated using a linear decision analytical model. Management costs were calculated from the published incidence of adverse events and health-care costs for treating adverse events in the United Kingdom, Germany, France and Italy.Results: Adverse event management costs were higher for sunitinib than for bevacizumab plus IFN. The average cost per patient for the management of grade 3-4 adverse events was markedly lower with bevacizumab plus IFN compared with sunitinib in the United Kingdom (euro1475 vs euro804), Germany (euro1785 vs euro1367), France (euro2590 vs euro1618) and Italy (euro891 vs euro402). The main cost drivers were lymphopaenia, neutropaenia, thrombocytopaenia, leucopaenia and fatigue/asthaenia for sunitinib; and proteinuria, fatigue/asthaenia, bleeding, anaemia and gastrointestinal perforation for bevacizumab plus IFN.Conclusion: The costs of managing adverse events are lower for bevacizumab plus IFN than for sunitinib. The potential for cost savings should be considered when selecting treatments for RCC. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
26. Illusory Price Increases after the Euro Changeover in Germany: An Expectancy-Consistent Bias.
- Author
-
Traut-Mattausch, Eva, Greitemeyer, Tobias, Frey, Dieter, and Schulz-Hardt, Stefan
- Subjects
PRICES ,DISCRIMINATION (Sociology) ,EXPECTANCY-value theory ,EURO ,SOCIAL role ,RESEARCH ,PRICING ,EUROPEAN currency unit ,ECONOMICS - Abstract
The aim of the present report is to review research demonstrating the role played by expectations for observed illusory price increases after the euro introduction in Germany. In laboratory experiments when participants are asked to estimate price changes in a restaurant following the euro introduction, the price estimates are found to be biased in the direction of the expectation of rising prices. The research also examines the extent to which a similar judgment bias is evident in other areas and how interventions counteract the bias. A further focus of the research is on the underlying process. In this respect the results show that the bias is based on a selective outcome correction process not previously described. Theoretical implications and practical implications for consumer policy issues are highlighted. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
27. Costs of inflammatory bowel disease in Germany.
- Author
-
Stark, Renee, König, Hans-Helmut, Leidl, Reiner, and König, Hans-Helmut
- Subjects
INFLAMMATORY bowel diseases ,MEDICAL care costs ,CROHN'S disease ,ULCERATIVE colitis ,THERAPEUTICS ,ECONOMICS ,COMPARATIVE studies ,ECONOMIC aspects of diseases ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research - Abstract
Introduction: Inflammatory bowel disease (IBD) is a chronic condition that afflicts young adults in their economically productive years. The goal of this study was to determine the costs of IBD in Germany from a societal perspective, using cost diaries.Methods: Members of the German Crohn's Disease and Ulcerative Colitis Association who had IBD were recruited by post, and those who agreed to participate documented their IBD-associated costs prospectively in a diary over 4 weeks. They documented their use of healthcare facilities, medications, sick leave and out-of-pocket expenditures, as well as general demographic information, the status and history of their IBD, and long-term disability. Item costs were calculated according to national sources. Cost data were calculated using non-parametric bootstrapping and presented as mean costs (year 2004) over 4 weeks.Results: The cost diaries were returned by 483 subjects (Crohn's disease: n = 241, ulcerative colitis: n = 242) with a mean age of 42 years and an average disease duration of 13 years (SD +/- 8.09). The cost diaries were regarded as 'easy to complete' by 89% of participants. The mean 4-week costs per subject were 1,425 Euros(95% CI 1201, 1689) for Crohn's disease and 1,015 Euros(95% CI 832, 1258) for ulcerative colitis. Of the total costs for Crohn's disease, 64% were due to indirect costs such as early retirement or sick leave and 32% were due to direct medical costs. In contrast, of the total costs for ulcerative colitis, 41% were due to direct medical costs and 54% to indirect costs.Conclusions: This is the first comprehensive cost study for Crohn's disease and ulcerative colitis in Germany. The most important economic factors that influenced the cost profiles of both diseases were the long-term productivity losses due to an ongoing inability to work and the cost of medications. Results indicate significant cost differences between Crohn's disease and ulcerative colitis. This data provides initial cost estimates that can be analysed further with respect to cost determinants and disease-specific costs in the future. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
28. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany.
- Author
-
Ehlken, Birgit, Ihorst, Gabriele, Lippert, Barbara, Rohwedder, Angela, Petersen, Gudula, Schumacher, Martin, Forster, Johannes, and PRIDE Study Group
- Subjects
RESPIRATORY infections ,JUVENILE diseases ,ECONOMIC impact ,RESPIRATORY syncytial virus ,PARAINFLUENZA viruses ,INFLUENZA viruses ,MEDICAL care costs ,OUTPATIENT medical care ,HOSPITAL care ,COMPARATIVE studies ,CROSS infection ,DEMOGRAPHY ,ECONOMIC aspects of diseases ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,HEALTH insurance reimbursement ,EVALUATION research ,COMMUNITY-acquired infections ,ORTHOMYXOVIRUS infections ,RESPIRATORY syncytial virus infections ,RNA virus infections ,ECONOMICS - Abstract
Data on the economic burden of lower respiratory tract infections (LRTI) in young children are lacking in Germany. The objective of the cost-of-illness study was to estimate the economic impact of community-acquired LRTI and nosocomial LRTI as well as of infections due to respiratory syncytial virus (RSV), parainfluenza viruses (PIV) and influenza viruses (IV). The economic analysis is part of the PRIDE study, a prospective, multi-centre, population-based epidemiological study on the impact of LRTI in children aged 0 to 36 months in Germany. The analysis includes children with community-acquired infections (1329 cases treated as outpatients, 2039 cases treated as inpatients) and nosocomial infections (90 cases). Medical services consumed were generated by chart abstraction and parental expenses data by telephone interviews within four weeks after physician visit or hospitalisation. Costs were evaluated from following perspectives: third party payer, parent and society. Total costs for outpatient treatment are Euro 123 per LRTI case. Stratified by virus type, total costs per case are Euro 163 (RSV), Euro 100 (PIV) and Euro 223 (IV). Total costs per hospitalised LRTI case amount to Euro 2579. Stratified by virus type, total costs per case are Euro 2772 (RSV), Euro 2374 (PIV) and Euro 2597 (IV). Total costs per nosocomial case are Euro 2814. Economic burden due to LRTI is Euro 213 million annually. It is concluded that treatment of LRTI in children up to age three causes a considerable economic burden in Germany. Presented results are the first data describing the economic burden of LRTI in young children assessed by means of the incidence data for Germany. This cost-of-illness study provides basic data for further decision-making, focusing on the economic assessment of preventive strategies for RSV, PIV and IV infections. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
29. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
- Author
-
Schädlich, Peter K., Zeidler, Henning, Zink, Angela, Gromnica-Ihle, Erika, Schneider, Matthias, Straub, Christoph, Brecht, Josef G., Huppertz, Eduard, and Schädlich, Peter K
- Subjects
LEFLUNOMIDE ,ANTIRHEUMATIC agents ,THERAPEUTICS ,COST effectiveness ,RHEUMATOID arthritis ,ARTHRITIS ,COMPARATIVE studies ,ECONOMIC aspects of diseases ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,STATISTICAL models ,ECONOMICS - Abstract
Objective: To quantify direct costs of medication and cost of illness (according to functional capacity) for patients with rheumatoid arthritis (RA) in Germany, allowing further use in a health economic evaluation of sequential therapy with disease-modifying antirheumatic drugs (DMARDs) in specialised, i.e. rheumatological, care in Germany.Design and Setting: The analysis was conducted from the societal perspective in Germany using a modelling approach, which was based on secondary analysis of existing data and on data from a sample of 583 patients from the German rheumatological database of 1998. Functional capacity was defined by the Hannover Functional Ability Questionnaire (HFAQ) scores. Costs were calculated from resources utilised and patients' work capacity. Direct costs consisted of outpatient medical services, inpatient treatment, long-term care and rehabilitation treatment. Indirect costs incurred by sick leave and premature retirement were quantified according to the human-capital approach.Main Outcome Measures and Results: Average total direct costs (year 1998-2001 values) per patient per year for continuous treatment with the selected DMARDs comprising costs for drugs, monitoring and treatment of adverse drug reactions (ADRs) were highest for intramuscular gold (sodium aurothiomalate) [euro 2106 (euro 1 approximately equal to $US 0.91; average of the period from 2000 through 2001)] followed by leflunomide (euro 2010), azathioprine (euro 1878), sulfasalazine (euro 1190), oral methotrexate (euro 708), and lowest for the antimalarials chloroquine/hydroxychloroquine (euro 684). There were additional yearly costs for RA-related non-DMARD medication of euro 554 per patient, including management of ADRs. Mean cost of illness (year 1998 values) excluding medication cost amounted to euro 17,868 per RA patient per year. Annual costs increased with increasing disability, i.e. decreasing functional capacity, of RA patients from euro 6029 per patient with more than 94% of functional capacity to euro 28,509 per patient with <20% of functional capacity. In general, there was a predominance of indirect costs in each of the categories of functional capacity, ranging between 74% and 87% of total (direct and indirect) annual costs per RA patient. Annual direct costs increased from euro 811 to euro 7438 per patient with increasing disability. Inpatient treatment was the predominant component of direct costs. Patients in the worst category (<20%) of function experienced hospital costs that were 6.5 times higher than those of patients in the best category (>94%).Conclusions: On the basis of the data presented it can be concluded that the results of this investigation are typical for patients in rheumatological care in Germany and can therefore be used in a health economic analysis of different DMARD sequences aimed at changing disease progression over time. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
30. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
- Author
-
Schädlich, Peter K., Zeidler, Henning, Zink, Angela, Gromnica-Ihle, Erika, Schneider, Matthias, Straub, Christoph, Brecht, Josef G., Huppertz, Eduard, and Schädlich, Peter K
- Subjects
LEFLUNOMIDE ,IMMUNOSUPPRESSIVE agents ,ANTIRHEUMATIC agents ,ANTI-inflammatory agents ,COST effectiveness ,RHEUMATOID arthritis ,CLINICAL trials ,COMPARATIVE studies ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,STATISTICAL models ,ECONOMICS - Abstract
Objective: To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into sequential therapy, consisting of the most frequently used disease-modifying antirheumatic drugs (DMARDs), for patients with rheumatoid arthritis in specialised, i.e. rheumatological, care in Germany.Design and Setting: The analysis was conducted from the societal perspective in Germany using an existing 3-year simulation model, which was adapted to the German healthcare system after secondary analysis of relevant publications and data. DMARD sequences including leflunomide were compared with those excluding leflunomide. Costs comprised direct costs incurred by treatment and indirect costs incurred by loss of productivity (sick leave and premature retirement) of rheumatoid arthritis patients. Effectiveness parameters were given by response years gained (RYGs) according to the American College of Rheumatology (ACR) criteria for 20%, 50% and 70% improvement (ACR20/50/70RYGs) and by QALYs gained (QALYGs). Costs, effects and QALYs were discounted by 5% per annum. In the base-case analysis, average values of costs, response years and QALYs were applied. Costs were in 1998-2001 values (euro 1 approximately equal to $US 0.91, average of the period from the year 2000 through 2001).Main Outcome Measures and Results: After 3 years, adding leflunomide was less costly and more effective than the strategy excluding leflunomide when total (direct and indirect) costs were considered. There were savings of euro 271,777 and 8.1, 4.3, 5.1 and 4.9 ACR20RYGs, ACR50RYGs, ACR70RYGs and QALYGs per 100 patients, respectively, obtained through adding leflunomide. Focusing on direct costs, adding leflunomide was more costly and more effective compared with excluding leflunomide, with an incremental cost effectiveness of euro 5004 per ACR20RYG, euro 9535 per ACR50RYG, euro 7996 per ACR70RYG, and an incremental cost utility of euro8301 per QALYG, after 3 years. The robustness of the results was shown in comprehensive sensitivity analyses. In the analysis of extremes, different combinations of the limits of cost, effectiveness and utility parameters were investigated. Adding leflunomide to sequential DMARD therapy remained dominant in 79% of the possible cases, i.e. was less costly and more effective than the strategy excluding leflunomide. Focusing on direct costs, adding leflunomide became dominant in 29% and remained more costly and more effective in 50% of possible cases.Conclusions: Our analysis suggests, with its underlying data and assumptions, that having leflunomide as an additional option in a DMARD treatment sequence extends the time patients benefit from DMARD therapy at reasonable additional direct costs. Adding leflunomide may even be cost saving when total (direct and indirect) costs are considered. As data on DMARD effectiveness were extracted from the results of clinical trials, real-world data from observational studies would be needed to corroborate the findings of the present analysis. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
31. Comparison of economic and environmental impacts between disposable and reusable instruments used for laparoscopic cholecystectomy.
- Author
-
Adler, S., Scherrer, M., Rückauer, K. D., Daschner, F. D., and Rückauer, K D
- Subjects
DISPOSABLE medical devices ,ENVIRONMENTAL impact analysis ,LAPAROSCOPY ,CHOLECYSTECTOMY ,GALLBLADDER surgery ,COST effectiveness ,STERILIZATION equipment ,LAPAROSCOPIC surgery ,SURGICAL instruments ,STERILIZATION (Disinfection) ,MEDICAL equipment reuse ,ASSETS (Accounting) ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,WASTE products ,COST analysis ,EVALUATION research ,ECONOMICS ,EQUIPMENT & supplies - Abstract
Background: The economic and environmental effects were compared between disposable and reusable instruments used for laparoscopic cholecystectomy. Special consideration was given to the processing of reusable instruments in the Miele G 7736 CD MCU washer disinfector and the resultant cost of sterilization.Methods: The instruments frequently used in their disposable form were identified with the help of surgeons. Thus, of all the instruments used for laparoscopic cholecystectomy, the disposable and reusable versions of trocars, scissors, and Veress cannula were compared.Results: For the case examined in this study, the performance of laparoscopic cholecystectomy with disposable instruments was 19 times more expensive that for reusable instruments. The higher cost of using disposable instruments is primarily attributable to the purchase price of the instruments. The processing of reusable instruments has little significance in terms of cost, whereas the cost for disposing of disposable instruments is the least significant factor. The number of laparoscopic cholecystectomies performed per year does not substantially influence cost. In the authors' opinion, assessment of the environmental consequences shows that reusable instruments are environmentally advantageous.Conclusions: Considering the upward pressure of costs in hospitals, disposable instruments should be used for laparoscopic cholecystectomy only if they offer clear advantages over reusable instruments. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
32. The applied economics of agriculture: introduction and overview.
- Author
-
Taylor, Mark P.
- Subjects
ECONOMICS ,AGRICULTURE ,RESEARCH - Abstract
We introduce and summarize the results of nine empirical studies that make up this special issue on agricultural economics. The research includes studies applied to the US, Bangladesh, Northern Ireland, Germany, Poland, Taiwan, Tunisia and Italy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.